Atomera Incorporated develops, commercializes, and licenses proprietary semiconductor technologies for the $700 billion global semiconductor industry. The company’s flagship innovation, Mears Silicon Technology (MST), is a patent-protected thin film of reengineered silicon designed to enhance transistor performance by enabling smaller, faster, and more power-efficient integrated circuits. MST addresses key engineering challenges in semiconductor manufacturing, including…
Atomera Incorporated develops, commercializes, and licenses proprietary semiconductor technologies for the $700 billion global semiconductor industry. The company’s flagship innovation, Mears Silicon Technology (MST), is a patent-protected thin film of reengineered silicon designed to enhance transistor performance by enabling smaller, faster, and more power-efficient integrated circuits. MST addresses key engineering challenges in semiconductor manufacturing, including drive current enhancement, leakage reduction, and variability control, without requiring significant modifications to existing fabrication processes or equipment. Atomera does not manufacture wafers or integrated circuits directly but instead licenses its technology and provides integration services to semiconductor designers and manufacturers.
Atomera generates revenue through licensing agreements, engineering services, and royalties. The company’s primary revenue streams include upfront license fees for research and development (R&D) and high-volume manufacturing (HVM) licenses, as well as ongoing royalties based on the sales of MST-enabled products. Additionally, Atomera offers MSTcad software, which allows customers to simulate the benefits of MST integration using Synopsys’ technology computer-aided design (TCAD) tools, and provides fee-based integration engineering services to assist customers in evaluating MST within their manufacturing flows. These services are typically structured under paid evaluation arrangements, joint development agreements (JDAs), or integration license agreements.
The company operates through the following segments:
• Technology Licensing: This segment focuses on commercializing MST by entering into license agreements with semiconductor manufacturers, including foundries, integrated device manufacturers (IDMs), and fabless semiconductor companies. Licenses are granted in two phases—R&D licenses for internal use and HVM licenses for commercial production—with upfront fees and royalties tied to product sales. The segment also includes revenue from MSTcad software licensing, which enables customers to model MST integration before physical implementation.
• Engineering Services: This segment provides fee-based integration and evaluation services to customers seeking to adopt MST technology. Services include depositing MST films on customer wafers, conducting test runs, and optimizing integration into existing manufacturing processes. These engagements often serve as a pathway to full commercial licensing agreements and are structured under JDAs or integration license agreements.
Atomera occupies a unique position within the semiconductor industry as a provider of additive, low-cost performance enhancement technology. The company competes with integrated device manufacturers, foundries, fabless semiconductor companies, and other intellectual property (IP) licensing firms that develop technologies to improve semiconductor performance. Unlike many competitors, Atomera’s MST technology is designed to be compatible with existing manufacturing tools and processes, reducing adoption barriers and capital expenditure requirements. The company’s competitive advantages include its extensive patent portfolio, with 119 U. S. and 130 international patents granted as of December 31, 2025, and its strategic partnerships with industry leaders such as Synopsys and a global semiconductor equipment vendor. These collaborations enhance Atomera’s credibility and accelerate customer adoption by leveraging established industry relationships.
Atomera’s customer base spans the semiconductor supply chain, including foundries, IDMs, fabless semiconductor manufacturers, wafer manufacturers, epitaxial equipment OEMs, and electronic design automation companies. Specific customers mentioned in the filing include a leading semiconductor provider, a major semiconductor foundry, a fabless RF semiconductor company, and Asahi Kasei Microdevices (AKM). The company’s technology targets applications in power devices, RFSOI devices, advanced CMOS integrated circuits, and compound semiconductors such as gallium nitride (GaN). Atomera’s engagements typically progress from initial technical evaluations to full commercial licensing, with customers often entering JDAs or integration agreements before committing to HVM licenses.
Sector:TechnologySector rationaleAtomera designs and licenses proprietary semiconductor technology (Mears Silicon Technology) and provides MSTcad software to semiconductor designers and manufacturers. Its revenue model is based on licensing fees, royalties, and engineering services for the integration of its intellectual property into integrated circuits, which falls squarely within the Technology sector's semiconductor and software domains.Industries:Semiconductor EDA SoftwareTechnologyPrimaryAtomera's core business is licensing its proprietary Mears Silicon Technology (MST) and providing MSTcad software for simulation, which fits the description of licensable semiconductor IP and design tools. The company generates revenue through upfront license fees and royalties from semiconductor designers and manufacturers without owning fabrication plants.IT ServicesTechnologySecondaryThe company has a dedicated Engineering Services segment that provides fee-based integration and evaluation services, such as depositing MST films on customer wafers and optimizing manufacturing processes.Classified using BQ-MICSCIK: 0001420520
Investment Thesis
▲ Bull case
Atomera Incorporated is positioned to capture significant value from the structural shift toward gate-all-around transistor architectures at 2nm and beyond, where its MST technology provides a critical solution for dopant diffusion control—a problem that directly impacts the performance and reliability of AI infrastructure chips. The company has already demonstrated measurable silicon results showing MST outperforms incumbent methods, and it is actively conducting customer-specific evaluations with two of the four global gate-around leaders (TSMC, Samsung, Intel, Rapidus), with discussions underway for the others. The lengthy evaluation timelines described—two to three months for Atomera’s processing plus several months for customer fab runs—indicate deep engagement rather than superficial interest, and the fact that customers are sending their proprietary wafers for testing signifies a high level of trust and technical validation. This positions Atomera to convert these engagements into joint development agreements (JDAs) and eventual royalty-bearing licenses as customers seek to de-risk adoption of MST in high-volume manufacturing, especially as the industry moves toward CFET architectures where MST’s interface engineering becomes even more essential. The strategic partnership with a major epi tool vendor further accelerates this path by providing Atomera with preferred access to customer fab flows and co-developed marketing credibility, reducing barriers to entry and increasing the likelihood that tool vendors will advocate for MST adoption to win semiconductor equipment sales.
In the GaN on silicon market, Atomera has achieved a breakthrough in mitigating the parasitic channel effect that has plagued RF GaN on silicon for over two decades—a fundamental materials science limitation that has constrained performance in wireless infrastructure, defense, satellite, and emerging 6G applications. Unlike power GaN, which requires extensive device fabrication and electrical testing for validation, RF GaN performance improvements from MST can be demonstrated through simpler material characterization, enabling faster customer adoption cycles. The company is already engaging with both 200mm and 300mm wafer customers, leveraging the cost advantages of silicon substrates to enable high-volume production pathways, and has expanded collaboration with Synopsys to ensure accurate TCAD modeling of MST in GaN devices—critical for customer confidence in simulation-to-silicon translation. This dual-track progress in both power and RF GaN, supported by ecosystem partners like InCyte, Texas State University, and Sandia, creates multiple near-term commercialization paths, with RF GaN offering a faster route to revenue due to lower validation hurdles, while power GaN represents a larger long-term opportunity. The ability to solve a 20-year-old industry problem with measurable, peer-recognized data significantly de-risks the technology’s value proposition and opens doors to licensing agreements that were previously unattainable due to performance limitations.
Atomera’s financial position has been materially strengthened by the $25 million registered direct offering at $5 per share, which netted $23.6 million in proceeds and brought its cash balance to $44.11 million as of March 31, 2026—more than double the $19.2 million at year-end 2025. This capital infusion, combined with disciplined expense management and a reaffirmed 2026 non-GAAP operating expense target of $18.5 million, provides a runway of over two years at current burn rates, eliminating near-term financing risk and allowing the company to focus exclusively on commercial execution. The raise occurred despite geopolitical uncertainty in February, indicating management’s ability to access capital even in volatile markets, and the use of an ATM offering prior to the registered direct ($3.2 million at $2.47 average price) demonstrates sustained investor demand for the stock at levels above historical trading ranges. With 38.7 million shares outstanding and no immediate dilution pressure, Atomera can now pursue lengthy customer qualification processes—such as the six-month gate-all-around fab runs described—without compromising operational stability, turning what was once a liquidity-constrained development stage into a well-capitalized execution phase where technical milestones can be pursued with patience and precision.
Atomera Incorporated is positioned to capture significant value from the structural shift toward gate-all-around transistor architectures at 2nm and beyond, where its MST technology provides a critical solution for dopant diffusion control—a problem that directly impacts the performance and reliability of AI infrastructure chips. The company has already demonstrated measurable silicon results showing MST outperforms incumbent methods, and it is actively conducting customer-specific evaluations with two of the four global gate-around leaders (TSMC, Samsung, Intel, Rapidus), with discussions underway for the others. The lengthy evaluation timelines described—two to three months for Atomera’s processing plus several months for customer fab runs—indicate deep engagement rather than superficial interest, and the fact that customers are sending their proprietary wafers for testing signifies a high level of trust and technical validation. This positions Atomera to convert these engagements into joint development agreements (JDAs) and eventual royalty-bearing licenses as customers seek to de-risk adoption of MST in high-volume manufacturing, especially as the industry moves toward CFET architectures where MST’s interface engineering becomes even more essential. The strategic partnership with a major epi tool vendor further accelerates this path by providing Atomera with preferred access to customer fab flows and co-developed marketing credibility, reducing barriers to entry and increasing the likelihood that tool vendors will advocate for MST adoption to win semiconductor equipment sales.
In the GaN on silicon market, Atomera has achieved a breakthrough in mitigating the parasitic channel effect that has plagued RF GaN on silicon for over two decades—a fundamental materials science limitation that has constrained performance in wireless infrastructure, defense, satellite, and emerging 6G applications. Unlike power GaN, which requires extensive device fabrication and electrical testing for validation, RF GaN performance improvements from MST can be demonstrated through simpler material characterization, enabling faster customer adoption cycles. The company is already engaging with both 200mm and 300mm wafer customers, leveraging the cost advantages of silicon substrates to enable high-volume production pathways, and has expanded collaboration with Synopsys to ensure accurate TCAD modeling of MST in GaN devices—critical for customer confidence in simulation-to-silicon translation. This dual-track progress in both power and RF GaN, supported by ecosystem partners like InCyte, Texas State University, and Sandia, creates multiple near-term commercialization paths, with RF GaN offering a faster route to revenue due to lower validation hurdles, while power GaN represents a larger long-term opportunity. The ability to solve a 20-year-old industry problem with measurable, peer-recognized data significantly de-risks the technology’s value proposition and opens doors to licensing agreements that were previously unattainable due to performance limitations.
Atomera’s financial position has been materially strengthened by the $25 million registered direct offering at $5 per share, which netted $23.6 million in proceeds and brought its cash balance to $44.11 million as of March 31, 2026—more than double the $19.2 million at year-end 2025. This capital infusion, combined with disciplined expense management and a reaffirmed 2026 non-GAAP operating expense target of $18.5 million, provides a runway of over two years at current burn rates, eliminating near-term financing risk and allowing the company to focus exclusively on commercial execution. The raise occurred despite geopolitical uncertainty in February, indicating management’s ability to access capital even in volatile markets, and the use of an ATM offering prior to the registered direct ($3.2 million at $2.47 average price) demonstrates sustained investor demand for the stock at levels above historical trading ranges. With 38.7 million shares outstanding and no immediate dilution pressure, Atomera can now pursue lengthy customer qualification processes—such as the six-month gate-all-around fab runs described—without compromising operational stability, turning what was once a liquidity-constrained development stage into a well-capitalized execution phase where technical milestones can be pursued with patience and precision.
Atomera Incorporated remains dependent on lengthy, uncertain customer qualification processes in its core gate-all-around and GaN markets, where the path to commercial revenue involves multiple sequential steps—simulation validation, silicon demonstration on partner structures, customer-specific wafer runs, fab integration, and finally licensing—that collectively span 12 to 24 months or more per engagement. Despite having measured silicon results with its strategic partner, the company has not yet secured a single joint development agreement (JDA) or revenue-generating license, and customer commitments remain limited to wafer exchanges for evaluation rather than firm purchase orders or development contracts. The CFO’s admission that Q1 2026 revenue was only $11 thousand—consisting of minor wafer delivery fees—and the expectation of Q2 revenue in the $50 thousand to $100 thousand range underscore the immaturity of monetization, with deferred revenue of $96 thousand indicating minimal near-term conversion of technical progress into billable activities. This prolonged sales cycle, combined with the absence of any disclosed financial terms from ongoing engagements, suggests that Atomera may be investing significant R&D and sales resources into customer education without commensurate commercial return, increasing the risk that technical superiority fails to translate into sustainable revenue streams.
The company’s dependence on a narrow set of high-end semiconductor customers—limited to four global gate-all-around leaders and a fragmented GaN ecosystem—creates significant concentration risk, where delays or shifts in strategy by any single customer could materially impact Atomera’s growth trajectory. Management acknowledged that memory manufacturers, while interested in MST for dopant diffusion control in next-generation DRAM and high bandwidth memory, are further behind in engagement than logic customers, and the RF GaN breakthrough, while promising, remains unvalidated at scale and dependent on third-party test partners for confirmation. The reliance on ecosystem partners like Synopsys for TCAD modeling and tool vendors for fab access introduces external dependencies where changes in partner priorities—such as a shift in Synopsys’ GaN roadmap or a tool vendor’s decision to prioritize competing technologies—could undermine Atomera’s go-to-market strategy. Furthermore, the lack of disclosed progress with STMicroelectronics beyond renewed discussions, despite prior failed attempts to commercialize a BCD power program, raises questions about the durability of IDM relationships and the ability to expand beyond niche applications into broad-based process integration.
Atomera’s operating expenses increased sequentially by $1.6 million from Q4 2025 to Q1 2026, driven in part by the reversal of a previously deferred executive bonus—a one-time accounting effect that masked underlying cost growth. While the CFO attributed the year-over-year increase in non-GAAP operating expenses to hiring a VP of Sales and VP of Marketing, the company continues to report GAAP and non-GAAP net losses, with Q1 2026 GAAP net loss at $6.1 million ($0.17 per share), only slightly better than the $5.2 million loss in Q1 2025 despite the significant cash raise. This suggests that the influx of capital is being absorbed by rising operational costs rather than being directed toward accelerated commercialization, and the company’s reaffirmed 2026 annual non-GAAP operating expense target of $18.5 million implies a burn rate that could deplete its $44.11 million cash balance in under three years if revenue does not scale meaningfully. With no clear near-term revenue inflection point disclosed—no expected license announcements, no JDA timelines, and no customer commitments beyond wafer testing—the bullish case assumes a successful conversion of technical validation into commercial agreements that has yet to materialize, leaving investors exposed to the risk that Atomera remains a pre-revenue technology developer dependent on continued equity financing to sustain operations.
Atomera Incorporated remains dependent on lengthy, uncertain customer qualification processes in its core gate-all-around and GaN markets, where the path to commercial revenue involves multiple sequential steps—simulation validation, silicon demonstration on partner structures, customer-specific wafer runs, fab integration, and finally licensing—that collectively span 12 to 24 months or more per engagement. Despite having measured silicon results with its strategic partner, the company has not yet secured a single joint development agreement (JDA) or revenue-generating license, and customer commitments remain limited to wafer exchanges for evaluation rather than firm purchase orders or development contracts. The CFO’s admission that Q1 2026 revenue was only $11 thousand—consisting of minor wafer delivery fees—and the expectation of Q2 revenue in the $50 thousand to $100 thousand range underscore the immaturity of monetization, with deferred revenue of $96 thousand indicating minimal near-term conversion of technical progress into billable activities. This prolonged sales cycle, combined with the absence of any disclosed financial terms from ongoing engagements, suggests that Atomera may be investing significant R&D and sales resources into customer education without commensurate commercial return, increasing the risk that technical superiority fails to translate into sustainable revenue streams.
The company’s dependence on a narrow set of high-end semiconductor customers—limited to four global gate-all-around leaders and a fragmented GaN ecosystem—creates significant concentration risk, where delays or shifts in strategy by any single customer could materially impact Atomera’s growth trajectory. Management acknowledged that memory manufacturers, while interested in MST for dopant diffusion control in next-generation DRAM and high bandwidth memory, are further behind in engagement than logic customers, and the RF GaN breakthrough, while promising, remains unvalidated at scale and dependent on third-party test partners for confirmation. The reliance on ecosystem partners like Synopsys for TCAD modeling and tool vendors for fab access introduces external dependencies where changes in partner priorities—such as a shift in Synopsys’ GaN roadmap or a tool vendor’s decision to prioritize competing technologies—could undermine Atomera’s go-to-market strategy. Furthermore, the lack of disclosed progress with STMicroelectronics beyond renewed discussions, despite prior failed attempts to commercialize a BCD power program, raises questions about the durability of IDM relationships and the ability to expand beyond niche applications into broad-based process integration.
Atomera’s operating expenses increased sequentially by $1.6 million from Q4 2025 to Q1 2026, driven in part by the reversal of a previously deferred executive bonus—a one-time accounting effect that masked underlying cost growth. While the CFO attributed the year-over-year increase in non-GAAP operating expenses to hiring a VP of Sales and VP of Marketing, the company continues to report GAAP and non-GAAP net losses, with Q1 2026 GAAP net loss at $6.1 million ($0.17 per share), only slightly better than the $5.2 million loss in Q1 2025 despite the significant cash raise. This suggests that the influx of capital is being absorbed by rising operational costs rather than being directed toward accelerated commercialization, and the company’s reaffirmed 2026 annual non-GAAP operating expense target of $18.5 million implies a burn rate that could deplete its $44.11 million cash balance in under three years if revenue does not scale meaningfully. With no clear near-term revenue inflection point disclosed—no expected license announcements, no JDA timelines, and no customer commitments beyond wafer testing—the bullish case assumes a successful conversion of technical validation into commercial agreements that has yet to materialize, leaving investors exposed to the risk that Atomera remains a pre-revenue technology developer dependent on continued equity financing to sustain operations.